Kite Pharma
Apr 02, 2021
A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers
Chimeric Antigen Receptor (CAR) Therapies have changed the treatment paradigm of hematological malignancies to a vast extent. These personalized therapies have not only evolved as a game-changer in the field of medicine but also in the lives of the patients. Until the last approvals made by Novartis and Kite Pha...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
